Physician

Indira Chervu, M.D.

According to 2025 Medicare claims, Indira Chervu, M.D. (NPI: 1235133869) practices nephrology in the Marietta, GA market, with the plurality of this provider's patient population coming from Cobb, GA. This provider's primary affiliated billing organization is GEORGIA KIDNEY ASSOCIATES, INC. (NPI: 1932183654; TIN: 58-1397948) and primary practice location at 30060-1171. Chervu is affiliated with the WellStar Clinical Partners Medicare ACO, LLC (ACO ID: A4803), participating under the MSSP model.

Chervu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 636 traditional Medicare patients, billed 7,850 HCPCS/CPT codes, and received $353,826 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,506 prescription claims across 548 beneficiaries totaling $353,159 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 235 claims. Open Payments data shows 15 records totaling $326. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have declined steadily, from $607,796 to $353,159. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,171 to $483.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,083	7,770	$375,876
2016	1,056	7,630	$385,962
2017	1,026	7,465	$365,075
2018	984	7,715	$365,260
2019	969	8,001	$367,366
2020	884	6,464	$331,008
2021	886	6,321	$343,441
2022	784	5,541	$309,458
2023	676	4,798	$263,133
2024	636	7,850	$353,826

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	546	7,847	$607,796
2016	581	8,156	$681,893
2017	542	6,808	$695,924
2018	482	5,587	$512,938
2019	479	4,593	$472,580
2020	455	3,906	$547,750
2021	458	3,703	$463,876
2022	491	3,402	$290,601
2023	476	3,398	$362,633
2024	548	3,506	$353,159

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	197	$8,343
2016	23	226	$8,687
2017	17	316	$11,526
2018	12	257	$10,619
2019	N/R	231	$7,065
2020	N/R	249	$8,417
2021	N/R	232	$7,538
2022	N/R	173	$3,573
2023	N/R	291	$6,094
2024	N/R	235	$4,207

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	240	348	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	206	295	$65
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	196	642	$40
82570	Creatinine level to test for kidney function or muscle injury	325	551	$5
81000	Manual urinalysis test with examination using microscope, non-automated	342	627	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	57	3,690	$66,420
Lokelma	Sodium Zirconium Cyclosilicate	54	2,172	$57,960
Jardiance	Empagliflozin	34	2,460	$39,838
Lanthanum Carbonate	Lanthanum Carbonate	17	734	$21,951
Veltassa	Patiromer Calcium Sorbitex	18	720	$20,222

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	11	$1,173
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	60	$1,035
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	49	$690
J7520	Sirolimus, oral, 1 mg	N	N/R	13	$532
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	30	$395

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$326	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Indira Chervu, M.D.?

Tedicare shows public-source Medicare data for Indira Chervu, M.D. (NPI 1235133869), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Indira Chervu, M.D. have ACO affiliation data?

Indira Chervu, M.D. is shown with ACO affiliation data for WellStar Clinical Partners Medicare ACO, LLC (MSSP, ACO ID A4803).

What billing organization is linked to Indira Chervu, M.D.?

Indira Chervu, M.D. is linked to GEORGIA KIDNEY ASSOCIATES, INC. (billing NPI 1932183654) in the available physician profile data.

Does Indira Chervu, M.D. have Open Payments data?

Indira Chervu, M.D. has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.